Top trader Najarian sees upside for Bristol Myers

Bristol-Myers Squibb R&D headquarters.
John Greim | LightRocket | Getty Images

CNBC "Halftime Report" trader Jon Najarian bought shares of Bristol-Myers Squibb on Wednesday after spotting unusual activity in the options market.

Najarian, whose CNBC Pro Model Portfolio is up 7 percent this year, believes the bulls are back following a 17 percent drop in the stock from its high in July.

In the past month, shares of BMY are down 7 percent, taking a hit along with the rest of the market. But as the stock appears to consolidate, Najarian thinks the path may be clear for it to move higher.

See his option trade below ...

More In Investing

CNBC ProAs growth stocks struggle, Wall Street analysts say bet on these value names
CNBC ProCramer says investors are misguided on Disney, expects theme parks and movies will bounce
CNBC ProTom Lee says the worst is over for ‘epicenter’ stocks, small caps, but warns on tech